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Background
The AIDS epidemic has contributed to an abrupt
increase of the incidence of Kaposi sarcoma, especially
in Sub-Saharan Africa, to values tens of times higher
than in the pre-epidemic era. There is, however, very lit-
tle literature concerning the clinical features of this dis-
ease and its management and outcome in HIV-positive
children in Africa.
Aim
To examine retrospectively a series of 70 HIV-positive
children with Kaposi sarcoma, from several centers in
South Africa, in order to describe the usual clinical pre-
sentation as well as the management and its impact on
the course of the disease.
Patients and methods
Data were analyzed from tumor registries and patient
records in four South African hospitals from January
1998 to December 2009.
Results
The average age in this series was 73 months. The ratio
of males to females was 1,65. The lesions were present
on skin in 32 out of 63 cases (50.79%), alone or in com-
bination with other sites. In 8 cases (12.69%) the tumor
was localized exclusively in the mouth, in a further
8 patients (12.69%) exclusively in the viscera, and in
6 patients (9.52%) only in the lymph nodes. Tuberculosis
was associated with Kaposi’s sarcoma in 9 cases out of
38 (23.68%). The mean CD4+ lymphocyte count was
440 (SD=385). Only 38 patients (54.28%) were taking
combined antiretrovirals at the time of diagnosis.
Twenty-nine cases (41.42%) received chemotherapy with
Bleomycine, Vincristine, and Adriamycin, alone or in
combination. While 32 patients (45.71%) died after an
average of 4 months, the average followup period for
the remaining children was 16 months, with a maximum
of 57 months.
Conclusions
Most of the time the clinical diagnosis was suggested by
the skin lesions; however, in a large percentage of cases
the tumor was hidden in the mouth, viscera, or lymph
nodes. The CD4+ lymphocyte count was not a predictor
of Kaposi sarcoma. The mortality remains high in South
Africa in spite of antiretroviral drugs and chemotherapy.
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